| 1 |
32791510 | Clinical Experience of Steroid Switch from Prednisone to Dexamethasone in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate. | 2021 |
1 |
| 2 |
33324967 | Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study. | 2021 Apr 1 |
1 |
| 3 |
33571020 | Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer. | 2021 Apr |
1 |
| 4 |
33650292 | Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment. | 2021 Sep |
1 |
| 5 |
33980956 | Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer. | 2021 May 12 |
3 |
| 6 |
34536949 | Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer. | 2021 Nov |
2 |
| 7 |
34944964 | Prognostic Impact of Sarcopenia in Patients with Metastatic Hormone-Sensitive Prostate Cancer. | 2021 Dec 17 |
1 |
| 8 |
32291107 | Re: Nobuaki Matsubara, Kim N. Chi, Mustafa Özgüroğlu, et al. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study. Eur Urol. 2020:77:494-500. https://doi.org/10.1016/j.eururo.2019.11.021. | 2020 Aug |
1 |
| 9 |
33116879 | PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate. | 2020 |
1 |
| 10 |
31183025 | Leukoerythroblastosis in castration-resistant prostate cancer: A clue to diffuse bone marrow carcinomatosis. | 2019 May 6 |
1 |
| 11 |
29630978 | The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer. | 2018 Aug |
2 |
| 12 |
29725416 | Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer. | 2018 May |
1 |
| 13 |
30194199 | Outcome of Patients with Metastatic Castration-resistant Prostate Cancer After PSA Progression with Abiraterone Acetate. | 2018 Sep |
2 |
| 14 |
27324190 | Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer. | 2017 Jan |
5 |
| 15 |
27489290 | Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer. | 2017 Feb 1 |
1 |
| 16 |
27601278 | Prostate-Specific Antigen Flare Phenomenon Induced by Abiraterone Acetate in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer. | 2017 Apr |
1 |
| 17 |
28126272 | Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer. | 2017 Jun |
1 |
| 18 |
28358937 | Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. | 2017 Nov 9 |
1 |
| 19 |
28744160 | Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives. | 2017 |
2 |
| 20 |
26879374 | Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study. | 2016 May |
2 |
| 21 |
26965561 | Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. | 2016 Nov |
2 |
| 22 |
27150425 | Inherited Variants in SULT1E1 and Response to Abiraterone Acetate by Men with Metastatic Castration Refractory Prostate Cancer. | 2016 Oct |
1 |
| 23 |
27278777 | Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials. | 2016 Jun 8 |
2 |
| 24 |
25829400 | Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients. | 2015 Jul 15 |
1 |
| 25 |
25981621 | A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer. | 2015 Aug |
3 |
| 26 |
24210911 | Evaluation of prostate-specific antigen response following cessation of abiraterone acetate: is there evidence for a withdrawal syndrome? | 2014 Feb |
1 |
| 27 |
24458472 | Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. | 2014 Mar |
1 |
| 28 |
24941984 | Potential value of rapid prostate-specific antigen decline in identifying primary resistance to abiraterone acetate and enzalutamide. | 2014 May |
1 |
| 29 |
24971430 | PSA flare after initiation of abiraterone acetate. | 2014 May |
1 |
| 30 |
25320340 | A phase 2 trial of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer and without prior chemotherapy (JPN-201 study). | 2014 Dec |
2 |
| 31 |
23023354 | Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma. | 2012 Jul-Sep |
1 |
| 32 |
21984773 | Emerging treatments for castrate-resistant prostate cancer. | 2011 Aug |
1 |
| 33 |
20159824 | Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. | 2010 Mar 20 |
1 |
| 34 |
19470933 | Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. | 2009 Aug 10 |
1 |